Drug Topics

DECEMBER 25, 2024

Check out this list of our top 5 most read digestive health stories from the year 2024.

98

98

Pharmacy Times

DECEMBER 25, 2024

This study evaluated factors affecting the duration of the infusion appointment times for 392 clinical trial patients.

65

65

Drug Topics

DECEMBER 25, 2024

Check out this list of our top 5 most read Total Pharmacy stories from the year 2024.

98

98

Pharmacy Times

DECEMBER 25, 2024

Panelists discuss how the main treatment goals for patients with primary biliary cholangitis (PBC) include improving liver biochemistry, preventing disease progression to cirrhosis, managing symptoms, and enhancing overall quality of life through regular monitoring and appropriate therapeutic interventions.

65

65

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Compounding Pharmacy of America

DECEMBER 25, 2024

Discover how compounding pharmacists provide customized medications, improve patient care, and address unique healthcare needs with precision and innovation. The post What Is A Compounding Pharmacist? appeared first on Compounding Pharmacy of America.

Compounding 52

Compounding Compounding Pharmacies Patient Care 52

Pharmacy Times

DECEMBER 25, 2024

Panelists discuss how some patients with primary biliary cholangitis (PBC) have an inadequate response to ursodeoxycholic acid and require second-line treatments, with options including obeticholic acid, seladelpar, and elafibranor, which improve bile acid homeostasis and reduce inflammation.

65

65

PharmExec

DECEMBER 25, 2024

In this part of his Pharmaceutical Executive video interview, Peter Ax, CEO of UpScriptHealth, discusses regulatory challenges and opportunities that telehealth companies face in 2025.

52

52

The Guardian - Pharmaceutical Industry

DECEMBER 25, 2024

Readers describe aggressive online promotions, Black Friday deals and special offers for prescription-only drugs After Andy King was told he was not eligible to receive weight-loss jabs on the NHS, he turned to the internet to order them privately. But before long, he was inundated with promotions. Every other advert on my social media feed is an offer to have a Black Friday deal on the drugs, he said.

52

52

PharmExec

DECEMBER 25, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

52

52

Pharmacy Times

DECEMBER 25, 2024

Gecacitinib is a novel inhibitor targeting both JAK and ACVR1.

50

50

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

The Guardian - Pharmaceutical Industry

DECEMBER 25, 2024

Guardian review finds many online pharmacies flouting strict advertising rules that govern prescription-only drugs Weight-loss injections are being aggressively marketed to British consumers through often illegal promotions, in a practice experts have described as a wild west industry of drug selling. The booming market for jabs such as Wegovy and Mounjaro has triggered a price battle among online pharmacies, with even high-street chains cashing in on the soaring demand.

46

46

Pharmacy Times

DECEMBER 25, 2024

Proper reporting of errors and near misses helps maintain compliance and improve patient safety.

50

50

The Guardian - Pharmaceutical Industry

DECEMBER 25, 2024

Drugs such as Wegovy amd Mounjaro are an attractive prospect for online businesses and traditional pharmacies as well as the firms that make them It is a trend rooted in profit-making. Adverts featuring prescription-only weight-loss medications are splashed across the internet and it is causing concern among experts. But the question remains: who is driving the boom?

41

41

Pharmaceutical Technology

DECEMBER 25, 2024

VMT-01 is under clinical development by Perspective Therapeutics and currently in Phase II for Metastatic Melanoma.

40

40

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Med Ed 101

DECEMBER 25, 2024

In this case scenario, I lay out a situation where cyclobenzaprine causes confusion. A 76-year-old female has a history of pain issues including RA, back pain, and knee pain. She is currently a resident at a long-term care facility. Her medications include: Two weeks ago, the primary provider decided to start cyclobenzaprine 10 mg TID […] The post Cyclobenzaprine Causes Confusion – Case Study appeared first on Med Ed 101.

Long-Term Care Facilities 52

Long-Term Care Facilities 52

Pharmaceutical Technology

DECEMBER 25, 2024

Glufosfamide is under clinical development by Eleison Pharmaceuticals and currently in Phase III for Metastatic Adenocarcinoma of The Pancreas.

40

40

Pharmaceutical Technology

DECEMBER 25, 2024

Dexamethasone sodium phosphate SR is under clinical development by Taiwan Liposome and currently in Phase III for Osteoarthritis Pain.

40

40

Pharmaceutical Technology

DECEMBER 25, 2024

Fosravuconazole is under clinical development by Eisai and currently in Phase II for Tinea Pedis (Athlete Foot).

40

40

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharmaceutical Technology

DECEMBER 25, 2024

EXO-CD24 is under clinical development by Nano24med and currently in Phase II for Acute Respiratory Distress Syndrome.

40

40

Pharmaceutical Technology

DECEMBER 25, 2024

AROC-3 is under clinical development by Arrowhead Pharmaceuticals and currently in Phase II for IgA Nephropathy (Berger's Disease).

40

40

Pharmaceutical Technology

DECEMBER 25, 2024

Apraglutide is under clinical development by Ironwood Pharmaceuticals and currently in Phase III for Short Bowel Syndrome.

40

40

Pharmaceutical Technology

DECEMBER 25, 2024

Gamma-PN is under clinical development by GPN Vaccines and currently in Phase II for Streptococcal Pneumonia.

Vaccines 40

Vaccines 40

Pharmaceutical Technology

DECEMBER 25, 2024

ACTUS-101 is under clinical development by Asklepios BioPharmaceutical and currently in Phase II for Pompe Disease.

40

40

Pharmaceutical Technology

DECEMBER 25, 2024

NB-4746 is under clinical development by Nura Bio and currently in Phase I for Amyotrophic Lateral Sclerosis.

40

40